SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-002268
Filing Date
2023-01-09
Accepted
2023-01-09 16:13:26
Documents
14
Period of Report
2023-01-04
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm232720d1_8k.htm   iXBRL 8-K 34139
2 EXHIBIT 3.1 tm232720d1_ex3-1.htm EX-3.1 16075
6 GRAPHIC tm232720d1_ex3-1img01.jpg GRAPHIC 17612
  Complete submission text file 0001104659-23-002268.txt   259633

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nbrv-20230104.xsd EX-101.SCH 3030
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbrv-20230104_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbrv-20230104_pre.xml EX-101.PRE 22593
8 EXTRACTED XBRL INSTANCE DOCUMENT tm232720d1_8k_htm.xml XML 3775
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 23518228
SIC: 2834 Pharmaceutical Preparations